Localisation of metastatic carcinoma by a radiolabelled monoclonal antibody

Immunolocalisation and imaging of small cell cancer xenografts by the IgG2a monoclonal antibody SWA11

“…The use of monoclonal antibodies (MAbs) for diagnosis (Cuttitta et al, 1984), imaging (Mach et al, 1981;Smedley et al, 1983) and now therapy (Lobuglio et al, 1986;Epenetos et al, 1987) of malignant disease is an increasingly realistic objective. MAbs generated against surface antigens of SCC can be divided according to the nature and expression of their target antigens into five main clusters, as defined at the International Workshop on SCC, London 1987 (Souhami et al, 1988).…”

A monoclonal antibody against human colon cancers.

“…Accordingly, the reduction of reactivity of A7 with irradiated cancers was thought that cancer cells changed their antigenicities by irradiation. Some investigators (Ferrands et al 1982;Smedley et al 1983) reported cases that radiolabeled monoclonal antibody was not detected in the patients subjected to irradiation therapy. But, there was no report on the reactivity of monoclonal antibody with …”

“…The reactivity of A7 with colorectal cancers was markedly reduced by preoperative irradiation. monoclonal antibody ; human colorectal cancers ; carcinoembryonic antigen Many monoclonal antibodies against human colorectal cancers have been prepared by cell fusion technique, using established cell lines as immunogen (Koprowski et al 1979;Smedley et al 1983; Kaszubowski et al 1984). However, cell lines might change their antigenicity during continuous cell cultures (Irie et al 1974;Dexter et al 1979;Laboi.sse et al 1981).…”

The detection of axillary lymph node metastases from breast cancer by radiolabelled monoclonal antibodies: a prospective study

“…However, there were cases when immunoscintigraphy using radiolabelled antibody (IgM or IgG) detected axillary lymph node metastases not suspected by clinical examination. Thus it appears that while immunoscintigraphy may be a useful adjunct to preoperative clinical assessment and is simple and safe, a major improvement in its accuracy is needed before it can replace axillary dissection and histological examination in the accurate staging of axilla in breast cancer.The detection of overt tumour deposits by means of gammacamera imaging and radiolabelled monoclonal antibodies to tumour-associated antigens (immunoscintigraphy) has met with encouraging results (Armitage et al, 1984;Epenetos, 1985;Leyden et al, 1986;Mach et al, 1981;Rainsbury, 1984;Smedley et al, 1983;William et al, 1984). However, most of these studies have been performed on patients with well documented and widespread disease; few being prospective studies of the value of monoclonal immunoscintigraphy in the initial staging of patients with malignant disease.…”

“…The detection of overt tumour deposits by means of gammacamera imaging and radiolabelled monoclonal antibodies to tumour-associated antigens (immunoscintigraphy) has met with encouraging results (Armitage et al, 1984;Epenetos, 1985;Leyden et al, 1986;Mach et al, 1981;Rainsbury, 1984;Smedley et al, 1983;William et al, 1984). However, most of these studies have been performed on patients with well documented and widespread disease; few being prospective studies of the value of monoclonal immunoscintigraphy in the initial staging of patients with malignant disease.…”